Name: UMIN ID:
Unique ID issued by UMIN | UMIN000034954 |
---|---|
Receipt number | R000039856 |
Scientific Title | Phase 1/2a, Double-blind, Placebo-controlled Study with an Open-label Extension of Ropinirole Hydrochloride Extended-Release Tablets -Explorative Assessment of the Safety, Tolerability, and Efficacy after Oral Treatment in Patients with Amyotrophic Lateral Sclerosis (ALS)- |
Date of disclosure of the study information | 2018/11/30 |
Last modified on | 2021/04/22 10:40:16 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2018/11/20 23:41:27 | ||
2 | Update | 2018/11/20 23:42:09 | UMIN ID1 |
|
3 | Update | 2019/04/17 21:55:33 | Recruitment status Date of IRB Last follow-up date |
|
4 | Update | 2019/05/26 21:41:05 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Last name of contact person Last name of contact person Zip code Address Organization Organization Address Address Tel |
|
5 | Update | 2019/09/13 06:50:57 | Recruitment status |
|
6 | Update | 2019/09/13 06:53:26 | Number of participants that the trial has enrolled |
|
7 | Update | 2020/11/21 09:25:53 | Date trial data considered complete Date analysis concluded |
|
8 | Update | 2021/04/22 10:40:16 | Recruitment status |